SAN

80.9

-0.21%↓

UCB

240.9

-2.71%↓

SHL.DE

36.86

-3.38%↓

ARGX

677

-1.34%↓

VIE

35.26

-0.11%↓

SAN

80.9

-0.21%↓

UCB

240.9

-2.71%↓

SHL.DE

36.86

-3.38%↓

ARGX

677

-1.34%↓

VIE

35.26

-0.11%↓

SAN

80.9

-0.21%↓

UCB

240.9

-2.71%↓

SHL.DE

36.86

-3.38%↓

ARGX

677

-1.34%↓

VIE

35.26

-0.11%↓

SAN

80.9

-0.21%↓

UCB

240.9

-2.71%↓

SHL.DE

36.86

-3.38%↓

ARGX

677

-1.34%↓

VIE

35.26

-0.11%↓

SAN

80.9

-0.21%↓

UCB

240.9

-2.71%↓

SHL.DE

36.86

-3.38%↓

ARGX

677

-1.34%↓

VIE

35.26

-0.11%↓

Search

Fagron

Uždarymo kaina

SektoriusSveikatos priežiūra

23.75 -0.42

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

23.65

Max

23.9

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-99K

45M

Pardavimai

-98K

476M

P/E

Sektoriaus vid.

19.557

60.328

Dividendų pajamingumas

1.64

Pelno marža

9.55

Darbuotojai

4,193

EBITDA

11M

98M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+20.59% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

1.64%

2.24%

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

149M

1.8B

Ankstesnė atidarymo kaina

24.17

Ankstesnė uždarymo kaina

23.75

Fagron Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-23 00:00; UTC

Svarbiausios naujienos

Australian Flash PMI Bounce in April Conceals Deeper Worries

2026-04-22 23:33; UTC

Uždarbis

SK Hynix Posts Record Quarterly Results Amid AI Boom

2026-04-22 22:40; UTC

Uždarbis

Correction to ServiceNow Posts 22% 1Q Revenue Growth Article

2026-04-22 22:10; UTC

Įsigijimai, susijungimai, perėmimai

ServiceNow Says $4 Billion Term Loan Credit Deal Will Help Finance Armis Security Deal

2026-04-22 21:11; UTC

Uždarbis

ServiceNow Posts 22% 1Q Revenue Growth, But Says Armis Deal Will Weigh on Margins

2026-04-22 21:01; UTC

Uždarbis

IBM Posts Higher 1Q Sales, Buoyed by AI -- Update

2026-04-22 23:46; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-04-22 23:46; UTC

Rinkos pokalbiai

Nikkei May Remain Rangebound; Middle East Conflict in Focus -- Market Talk

2026-04-22 23:34; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Gold Falls as U.S.-Iran Cease-Fire Keeps Inflation Concerns High -- Market Talk

2026-04-22 23:16; UTC

Uždarbis

SK Hynix: Quarterly Revenue, Profits at All-Time High in 1Q

2026-04-22 23:15; UTC

Uždarbis

SK Hynix: Operating Profit Margin Reached Record 72% in 1Q

2026-04-22 22:54; UTC

Uždarbis

SK Hynix 1Q Net Profit Beat FactSet-Compiled Consensus

2026-04-22 22:54; UTC

Uždarbis

SK Hynix 1Q Net KRW40.346T Vs. Net KRW8.108T >000660.SE

2026-04-22 22:52; UTC

Uždarbis

SK Hynix 1Q Oper Pft KRW37.610T Vs. Pft KRW7.441T >000660.SE

2026-04-22 22:51; UTC

Uždarbis

SK Hynix 1Q Rev KRW52.576T Vs. KRW17.639T >000660.SE

2026-04-22 22:31; UTC

Uždarbis

Sandfire CEO: Delivery Risk, Input Cost Pressure Could Rise Quickly If Situation Deteriorates

2026-04-22 22:31; UTC

Uždarbis

Sandfire CEO: First, Second Order Impacts of Middle East Conflict Remain Hard to Predict

2026-04-22 22:30; UTC

Uždarbis

Sandfire CEO: Middle East Conflict Creates Significant Risk in Global Supply Chains

2026-04-22 22:30; UTC

Uždarbis

Sandfire: FY26 Underlying Operating Unit Costs Expected to 'Materially Aligned' With Guidance

2026-04-22 22:29; UTC

Uždarbis

Sandfire Resources 3Q Unaudited Underlying Ebitda $220 Million

2026-04-22 22:28; UTC

Uždarbis

Sandfire Resources 3Q Unaudited Sales Revenue $408 Million

2026-04-22 22:28; UTC

Uždarbis

Sandfire Resources 3Q Motheo Underlying Operating Unit Cost $44/Ton Ore Processed

2026-04-22 22:27; UTC

Uždarbis

Sandfire Resources 3Q Matsa Underlying Operating Unit Cost $95/Ton Ore Processed

2026-04-22 22:06; UTC

Rinkos pokalbiai
Uždarbis

Tesla Paid Robotaxi Miles Nearly Doubled Quarter-Over-Quarter -- Market Talk

2026-04-22 21:55; UTC

Įsigijimai, susijungimai, perėmimai

ServiceNow Says $4B Term Loan Credit Deal Will Help Finance Armis Security Deal

2026-04-22 21:47; UTC

Uždarbis

Lam Research Stock Jumps on Strong Earnings -- Barrons.com

2026-04-22 21:37; UTC

Uždarbis

Texas Instruments Reports Solid Earnings. The Stock Is Up. -- Barrons.com

2026-04-22 21:34; UTC

Uždarbis

Tesla Surprises Wall Street With Better Profits, $1.4 Billion in Free Cash Flow -- 3rd Update

2026-04-22 21:29; UTC

Uždarbis

Lam Research Stock Jumps on Strong Earnings -- Barrons.com

2026-04-22 21:20; UTC

Rinkos pokalbiai
Uždarbis

Tesla Expands Manufacturing to Chips -- Market Talk

Akcijų palyginimas

Kainos pokytis

Fagron Prognozė

Kainos tikslas

By TipRanks

20.59% į viršų

12 mėnesių prognozė

Vidutinis 19.5 EUR  20.59%

Aukščiausias 19.5 EUR

Žemiausias 19.5 EUR

Remiantis 1 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Fagron kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

1 ratings

1

Pirkti

0

Laikyti

0

Parduoti

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Fagron

Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide. It operates in three segments: Essentials, Brands, and Compounding Services. The company also innovates concepts, vehicles, and formulations for pharmaceutical compounding. Its products include DiluCap, a line of excipients to compound every capsule formulation; Imuno TF Complex helps in regulation of immune responses; Pigmerise, a natural phytocomplex for hypopigmentation disorders; Pentravan uses for avoiding first-pass metabolism and preventing gastrointestinal erosion; Nourisil MD, a first line therapy for prevention and treatment of scars ang keloids; Neogen, a line of hair care products; TrichoConcept used to treat alopecia; Fagron Advanced Derma for basic skincare, compound pharmaceutical treatment, and individualized dermatological care; and SyrSpend SF that provides pharmaceutical stability, dosage consistency, and patient comfort. In addition, the company offers education and training program to prescribers and pharmacists through the Fagron Academy. The company was formerly known as Arseus NV and changed its name to Fagron NV in January 2015. Fagron NV was founded in 1990 and is based in Nazareth, Belgium.
help-icon Live chat